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Abstract
Heme oxygenase-1 (HO1) degrades heme to carbon monoxide (CO), biliverdin, and ferrous iron. Through these
products, HO1 mitigates cellular injury by exerting anti-oxidant, anti-apoptotic, and anti-inflammatory effects.
Several lines of evidence indicate that angiogenic factors, such as vascular endothelial growth factor A (VEGF)
and stromal cell-derived factor 1 (SDF1), mediate their proangiogenic action in endothelial cells and endothelial
progenitor cells through induction of HO1, and reciprocally, VEGF and SDF1 are enhanced by HO1 overexpres-
sion. Ferrous iron released during the breakdown of free heme by HO1 is an extremely pro-oxidative molecule
that can be rapidly removed by ferritin. Of note, this iron sequestering protein also has been shown to exert some
proangiogenic effects. Moreover, our recent data indicate that HO1 is an important mediator of differentiation
and function of stem cells, including endothelial and myoblasts progenitors. All of this makes HO1 a promising
target for novel cardiovascular therapies. The aim of this review is to discuss the existing knowledge and to pro-
pose the therapeutic approaches, which have to consider the necessity of tight regulation of HO1 expression.
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Introduction
The treatment of cardiovascular disorders such as
coronary artery disease or peripheral artery disease,
which are directly dependent on inadequate blood flow
and insufficient oxygen content in tissues (hypoxia), still
remains a challenging and difficult entity to manage with
current surgical and standard medical procedures. Per-
cutaneous transluminal coronary angioplasty, a life-sa-
ving medical procedure for acute myocardial infarction
has its limitations, such as reocclusion and late resteno-
sis. Sudden occlusion of a major coronary artery and
acute myocardial ischemia causes rapid death of cardio-
myocytes and vascular cells in the ischemic area (Oli-
vetti et al., 1996). Reduced oxygen content from blood
creates a condition in which the restoration of circula-
tion results in inflammation and oxidative damage from
reactive oxygen species (ROS). In fact, oxidative stress
plays a major role in the pathophysiology of cardiac dis-
orders. Upregulation of stress-inducible antioxidant pro-
teins such as manganese superoxide dismutase, peroxi-
somal catalase, glutathione peroxidase-1 and heme oxy-
genase 1 (HMOX1, HO1) constitutes a defense system
for the heart enabling it to cope with an ischemic episo-
de [reviewed in: (Jazwa et al., 2007)]. Insufficient and
diminished with age antioxidant activity of these enzy-
mes leads to inefficient defenses and worsening of symp-
toms. It is noteworthy that impairment of these protec-
tive reactions can be restored by gene transfer.
Gene therapy involves the insertion of a functional
gene into cells to correct a cellular dysfunction or to pro-
vide a new cellular function. Recently, this procedure has
been successfully used in the treatment of different
monogenic diseases such as severe combined immuno-
deficiency syndrome (SCID) (Aiuti et al., 2009; Cavaz-
zana-Calvo et al., 2000; Hacein-Bey-Abina et al., 2002),
β-thalassemia (Cavazzana-Calvo et al., 2010; Roselli et al.,
2010), adrenoleukodystrophy (Cartier et al., 2009) and
Leber’s congenital amaurosis (Maguire et al., 2009). The
last two decades have also led to a significant progress in
our understanding of the pathophysiology of heart failure
at the molecular and cellular level, which created new
possibilities of interventions available for gene therapy
[reviewed in: (Rissanen and Yla-Herttuala, 2007)].
Several years of preclinical experimentation demon-
strated that cardioprotection can be conferred by many
different agents able to restore the function of failing
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cardiomyocytes. However, far from being successful in
humans, this method still needs to be optimized by the
choice of the most efficient transgene, proper route of
administration, dose and gene carrier (Yla-Herttuala et
al., 2004).
Myocardial ischemia triggers a spontaneous angio-
genic response which is a growth of new blood vessels
from the preexisting ones. Among many different agents
precisely regulating this process, vascular endothelial
growth factor A (VEGFA, VEGF) has been shown to play
a pivotal role in its initiation. This protective angiogenic
response is, however, usually not sufficient (Sasayama
and Fujita, 1992). Importantly, angiogenesis can be sti-
mulated in vivo and therefore represents an excellent
therapeutic target for the treatment of cardiovascular
disease.
VEGF, as already mentioned, is a critical regulator
of angiogenesis that stimulates proliferation, migration,
and proteolytic activity of endothelial cells (Ferrara,
1999), and is undeniably one of the well-studied factors
for therapeutic angiogenesis for limb and cardiac repair
[reviewed in: (Jazwa et al., 2007; Yla-Herttuala and Ali-
talo, 2003)]. VEGF expression is regulated by a variety
of different stimuli among which the most potent indu-
cer is hypoxia (Neufeld et al., 1999). We have previously
shown that HO1 also upregulates the expression of
VEGF (Dulak et al., 2002; Jazwa et al., 2006) and is ne-
cessary for proper function of stromal cell-derived factor
1 (CXCL12, SDF1) (Deshane et al., 2007), the cytokine
responsible for homing of endothelial progenitors and
activation of mature endothelial cells. In fact, we discove-
red that HO1 functions both upstream and downstream
of VEGF and SDF1 (Grochot-Przeczek et al., 2010), in-
ducing their expression and being required for the pro-
per response of endothelial or endothelial progenitor
cells to VEGF or SDF1 stimulation (Fig. 1). Thus, both
the direct and indirect protective and stimulatory effects
on the vascular bed make HO1 a promising target for the
improvement of treatment techniques in cardiovascular
disorders.
Heme oxygenase and its isoforms
Heme oxygenases, HO1 and HO2, are two enzymes
that catalyze the first, rate-limiting step in degradation
of heme (Maines, 1997). Both isoforms cleave the α-
meso carbon bridge of heme, yielding equimolar quanti-
ties of carbon monoxide, ferrous iron (Fe2+) and bili-
verdin (Tenhunen et al., 1968, Maines et al., 1986). The
breakdown of heme to these smaller compounds has its
own significance in essential cellular metabolism -- car-
bon monoxide has anti-inflammatory properties, biliver-
din and free iron bound to a heavy chain ferritin (H-fer-
ritin) are very efficient antioxidant molecules. These
three enzymatic products, together with bilirubin resul-
ting from conversion of biliverdin by biliverdin reductase
(BVR), play a critical role counterbalancing oxidative
stress and inflammation (Loboda et al., 2008; Maines,
1988). All together, these molecules have cytoprotec-
tive, proangiogenic and anti-apoptotic properties and are
claimed to be the second, after glutathione, most impor-
tant part of anti-oxidative protection system [reviewed
in: (Dulak and Jozkowicz, 2003)].
HO1 is a 32-kDa microsomal protein considered to
be a protective, early stress-response agent that may
have additional non-enzymatic activities related to its
mitochondrial localization (Slebos et al., 2007) and nu-
clear translocation (Lin et al., 2007). The expression of
HO1 is generally very low in normal tissues, apart from
liver and spleen, where it participates in the processing
of senescent or damaged erythrocytes and in protection
against oxidative damage caused by free porphyrins
(Tenhunen et al., 1968). In all tissues, low basal expres-
sion of HO1 can be strongly and quickly upregulated by
a wide variety of stimuli that cause oxidative stress, in-
cluding its substrate heme, heavy metals, cytokines,
ultraviolet rays, lipopolysaccharide, hydrogen peroxide,
growth factors, nitric oxide and also by carbon monoxide
(CO) [reviewed in: (Ryter et al., 2006)].
HO2 is a 36-kDa protein which, in contrast to HO1,
is constitutively and highly expressed in brain and testes
(Rotenberg and Maines, 1990). Unlike HO1, HO2 does
not seem to play any important role in conferring cyto-
protection against oxidative stress. However, this second
HO isoform has been shown to directly interact with the
large conductance calcium-activated K+ (BK) channels,
and this complex has been suggested to play an im-
portant role in carotid body oxygen sensing (Williams
et al., 2004).
Intriguing biological functions of BVR
HO1 activity is directly associated with BVR. Alt-
hough the latter one was, for a long time, considered the
sole enzyme that converts biliverdin to bilirubin, recent
years have revealed unique features of this protein,
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Fig. 1. Schematic model for HO1 signalling pathways and their effects on angiogenesis. Chemokine SDF1 is released at the site
of injury (e.g., during tissue ischemia) and induces HO1 in endothelial (progenitor) cell. CO, one of the products of heme de-
gradation, promotes migration of these cells and vascular repair. Pro-inflammatory cytokines acting on vascular smooth muscle
cell cause iNOS up-regulation, which further leads to increased NO synthesis and HO1-mediated production of VEGF. VEGF
acts on endothelial (progenitor) cells through VEGF receptor 1 (VEGFR1) or VEGF receptor 2 (VEGFR2). The proangiogenic
effects of this agent involve, among others, HO1 upregulation
which are not related to its reductase capacity. Posses-
sing the activity of a serine/threonine kinase, BVR is in-
volved in glucose metabolism, control of cell growth and
apoptosis and accordingly may play a role in pathogene-
sis of many disorders like diabetes or cancer. On the
other hand, being a leucin zipper-like DNA binding pro-
tein, it can act as a transcription factor for activator pro-
tein 1-regulated genes [reviewed in: (Florczyk et al.,
2008)]. As such BVR might specifically bind to HO1 pro-
moter and mediate enzyme upregulation in response to
oxidative stress (Ahmad et al., 2002) – Figure 1. A tight
link between HO1 and BVR has been confirmed in 293A
kidney cells, where silencing of BVR gene with siRNA at-
tenuated arsenite-mediated induction of HO1 and increa-
sed cell apoptosis (Miralem et al., 2005). Very recently
we have demonstrated that enhanced activity of BVR,
obtained with a doxycycline-induced Tet-On gene
expression system, increased the expression of HO1 and
was protective for NIH3T3 fibroblasts kept under stres-
sful conditions arising from anti-cancer drugs treatment,
cisplatin and doxorubicin. The effect was most probably
related to PKC α/β activity as its inhibition reversed
BVR action (Florczyk et al., 2010a). So far, data concer-
ning BVR expression in cancer are limited. Neverthe-
less, increased levels of BVR have been detected in kid-
ney cancer cells and acute myeloid leukemia [reviewed
in: (Florczyk et al., 2008)]. If this is a typical feature of
different tumors, the strategy based on inhibition of BVR
could be considered as an anti-cancer therapy. On the
other hand, gene transfer-mediated overexpression of
BVR in normal cells might provide protection against
potential cardiotoxic effects of chemotherapeutics (Outo-
muro et al., 2007). In this sense, increased expression
of BVR might be of potential therapeutic significance in
cardiac injuries.
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Regulation of rodent Ho1 and human HO1 gene
HO1 has been originally identified in rats as heat
shock protein 32 (HSP32) because its expression is
induced under stress conditions via heat shock factors,
which activate heat shock element (HSE) within Ho1
promoter (Muller et al., 1987). Further analyses of the
human HO1 and mouse Ho1 gene revealed a multiplicity
of cis-acting DNA response elements serving as potential
binding sites for transcription factors activated by dif-
ferent stimuli, which explains the highly inducible nature
of this gene in both species.
A common feature for many agents capable of indu-
cing HO1 is their electrophilic chemistry and generation
of reactive oxygen and/or nitrogen species, which causes
the activation of the transcription factor nuclear factor
erythroid 2-related factor 2 (NF-E2-related factor 2,
NRF2) (Florczyk et al., 2010b) (Fig. 2A). NRF2 belongs
to a subset of the bZip family members that share a Cap
“n” Collar domain and is maintained in the cytoplasm
through binding to the cytoskeletal-associated protein
Kelch-like ECH-associated protein 1 (KEAP1). Under
normal conditions, NRF2 is sequestered in cytoplasm by
KEAPl. The situation changes under stressful condi-
tions, when electrophiles and/or ROS cause dissociation
of NRF2 from KEAP1. As a consequence, NRF2 trans-
locates to the nucleus and binds to antioxidant response
element (ARE) within the promoter region of cytoprotec-
tive genes involved in electrophile conjugation, excretion
of xenobiotics, ROS scavenging and stabilization of cellu-
lar redox potential. In this way NRF2 also activates HO1.
Free heme, the primary substrate for HO1, can act
through NRF2 and increases the mRNA levels and acti-
vity of this protein by several folds (Yoshida et al., 1988).
Many different factors (dimers, both hetero and homo-
dimers) can bind to ARE including JUN, FOS, CREB,
ATF, MAF and the Cap'n'Collar/basic leucine Zipper
CNC-bZIP subclasses of the basic-leucine zipper (b-ZIP)
family of transcription factors. These include activator
protein 1, JUNB and JUND, NF-κB, upstream stimula-
tory factors (USF1 and USF2), hypoxia-inducible factor
1α (HIF1α), sterol regulatory element binding protein
(SREBP-1), peroxisome proliferator-activated receptors-
gamma (PPAR-γ), and others [reviewed in: (Jazwa and
Cuadrado, 2010; Loboda et al., 2008)].
Small MAF family proteins also interact with other
bZip members to repress HO1. These are BACH1 and
BACH2 (Oyake et al., 1996) and the p65 isoform of
NRF1 (Wang et al., 2007). BACH1 contains multiple co-
pies of a cysteine–proline motif surrounding the bZip do-
main that binds heme, thus leading to a decrease in its
DNA-binding activity (Ogawa et al., 2001). This hypoxia-
inducible heme-regulated transcriptional repressor has
two functions that seem to be important for HO1 regula-
tion. Firstly, similar to NRF2, it can bind MAF proteins
and then acts via ARE of the HO1 promoter; but, in con-
trast to NRF2, it represses HO1 transcription (Sun et
al., 2002). Secondly, BACH1 binds heme with a high af-
finity, and this BACH1-heme interaction prevents
BACH1 binding to ARE (Ogawa et al., 2001); therefore,
heme abrogates the repressor function of BACH1. Heme
also has the ability to regulate the nuclear export of
BACH1 (Suzuki et al., 2004).
HIF1α is another important regulator of HO1 (Lee
et al., 1997) – Figure 2B. HIF1 is a basic helix-loop-helix
heterodimeric transcription factor that consists of two
subunits: oxygen-sensitive (HIF1α) and oxygen-insensi-
tive constitutively expressed (HIF1β). HIF1α and HIF1β
heterodimer binds to the hypoxia responsive element
(HRE) in the promoter region of various genes whose
products like erythropoietin, VEGF and mouse Ho1, to
mention a few, play an adaptive role under hypoxic con-
ditions (Semenza, 2004). Among multiple HIF isoforms,
HIF1α and HIF2α are the best characterized. HIF2α has
a similar structure to HIF1α, but in contrast to widely
present HIF1α, the occurrence of HIF2α is restricted to
certain tissues such as heart, lungs, kidney and endo-
thelium (Stachurska et al., 2010; Wiesener et al., 2003).
At normal oxygen tension, the HIF1α subunit is rapidly
degraded. Degradation is mediated by a family of prolyl
hydroxylases (PHD1, 2 and 3) that hydroxylate proline
residues in the oxygen-dependent degradation domain of
HIF1α for recognition by the von Hippel-Lindau (VHL)
complex that subsequently targets it for degradation via
proteosome. PHDs need the presence of oxygen, iron,
and 2-oxoglutarate (2-OG), and therefore their activity
can be diminished by hypoxia, iron chelators, or 2-OG
analogues such as dimethyloxaloylglycine (DMOG) [revie-
wed in: (Loboda et al., 2008)].
Apart from HSE, ARE, and HRE, many other posi-
tive regulatory elements have been found in the HO1
promoter, for e.g. cadmium-responsive element, SMAD-
binding element, consensus binding sites for AP 1, speci-
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Fig. 2. Schematic model for HO1 gene regulation via NRF2, HIF1α and HSF. A) HO1 can be induced by its substrate heme as
well as by a variety of agents increasing intracellular levels of ROS. ROS induce ubiquitin-dependent proteasomal degradation
of KEAP1 (dotted line) enabling the NRF2 translocation to the nucleus and, in the form of heterodimer with small MAF proteins,
activation of antioxidant response element (ARE). BACH1 is a transcriptional repressor of the HO1 gene in human cells. Under
normal conditions, BACH1 is associated with small MAF proteins and limits the interaction between MAF and NRF2. Heme
limits BACH1 expression and stabilizes NRF2, which can form heterodimers with MAF. In the presence of high levels of heme
and oxidative stress, BACH1 is exported from the nucleus and degraded (dotted line), which allows derepression of the HO1
gene. B) Hypoxic regulation of HO1 involves activation of the hypoxia response element (HRE). In normoxia, HIF1α is hydroxy-
lated by proline hydroxylases (PHDs) in the presence of O2, Fe
2+, 2-oxoglutarate (2-OG) and ascorbate. Hydroxylated HIF1α (OH)
is directed to ubiquitin-dependent proteaseomal degradation (dotted line). Under hypoxic conditions, iron chelators (deferox-
amine) or 2-OG analogues (DMOG) proline hydroxylation is inhibited, which leads to HIF1α accumulation and translocation to
the nucleus. There, HIF1α dimerises with HIF1β and binds to HRE. C) Cells exposed to elevated temperatures or other stress
stimuli respond by an increased expression of heat shock proteins, such as HO1. The stress response is controlled primarily
at the transcription level by a heat shock factor (HSF). In unstressed cells, HSF is present in the cytoplasm and the nucleus in
a monomeric form that has no DNA binding activity. In response to stress, the monomeric HSFs combine into trimers
and accumulate within the nucleus where they bind to heat shock element (HSE)
ficity protein 1, nuclear factor-9B (NF-κB) and activator
protein 2, STATx, and upstream stimulatory factor [re-
viewed in: (Jazwa and Cuadrado, 2010; Loboda et al.,
2008)].
Polymorphisms in the human HO1 promoter
To date, three polymorphisms in the 5’flanking re-
gion of the human HO1 gene have been described: a GT
dinucleotide length polymorphism, and two single nu-
cleotide polymorphisms, -1135A/G and -413A/T (Exner
et al., 2004). All of them can modulate the level of HO1
transcription that has been associated with the incidence
and/or progression of a variety of diseases.
The most common variation in HO1 expression le-
vels in the human population appears to be due to dif-
ferent lengths of the GT repeats. The GT repeat length
ranges from 12 to 40 and usually shows a bimodal distri-
bution, with the median length of the short allele being
around 23 repeats and that of the long allele being
around 30 dinucleotide GT repeats in different popula-
tions studied (Exner et al., 2004). This purine-pyrimi-
dine-alternating sequence, possessing Z-conformation
potential, can negatively affect transcription of HO1
(Hill-Kapturczak et al., 2003). Longer GT sequences in
this region have been associated with attenuated HO1
transcriptional activity and weaker response to oxidative
stress (Hirai et al., 2003; Takahashi et al., 1999; Yamada
et al., 2000).
Although the recently performed large scale analysis
did not confirm a meaningful effect of HO1 promoter
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polymorphism on coronary artery disease or myocardial
infarction (Lublinghoff et al., 2009), there are many cli-
nical data indicating that individuals carrying fewer repe-
ats and thus having stronger HO1 expression are less pro-
ne to certain cardiovascular pathologies. Thus, the pre-
sence of longer, less active alleles was associated with an
increased risk of higher incidence of coronary artery
disease in type 2 diabetic or hemodialyzed patients (Bry-
dun et al., 2007; Chen et al., 2002), elevated rate of reste-
nosis after balloon angioplasty (Gulesserian et al., 2005)
or more frequent aortic aneurysms (Morgan et al., 2005)
and ischemic cerebrovascular events (Funk et al., 2004).
Moreover, among patients with peripheral artery disease,
those carrying longer HO1 alleles had higher rates of myo-
cardial infarction, percutaneous coronary interventions,
and coronary bypass operations (Dick et al., 2005). We
have recently demonstrated that primary human umbili-
cal vein endothelial cells (HUVEC) carrying shorter HO1
alleles demonstrated better antioxidative status (Taha et
al., 2010). These cells not only survived better under
oxidative stress conditions, but also proliferated more
effectively in response to VEGF, and produced less
proinflammatory mediators (Taha et al., 2010). This
indicates, for the first time, a significance of small and
perhaps also diagnostically significant variations in HO1
expression in vasculature.
HO1 in the vascular system
Angiogenesis, the process of creating new blood ve-
ssels from preexisting ones, is a key step in multiple
physiologic and pathologic processes such as wound
healing, menstruation cycle, tumor growth and meta-
stasis (Ferrara, 1999). Under normal conditions, the
process of angiogenesis is precisely regulated by a ba-
lance of multiple pro- and antiangiogenic factors. The
impairment of pregnancy in animals lacking the functio-
nal Ho1 gene (Ho1-/-) and the significant mortality
of Ho1-/- embryos (Poss and Tonegawa, 1997) might sug-
gest a meaningful role of HO1 in prenatal angiogenesis.
In fact, several studies that demonstrated the impor-
tance of HO1 in the vascular system, including vascular
tone regulation, anti-smooth muscle proliferation, anti-
endothelial apoptosis, and angiogenesis [reviewed in:
(Dulak et al., 2008)] indicated that this protein may be
important in postnatal angiogenesis.
The first study linking HO1 to the process of new
blood vessels formation was published by Deramaudt
and coworkers (1998) who showed that overexpression
of HO1 in endothelial cells enhances their proliferation.
Additional experiments confirmed that HO1 promotes
endothelial cell cycle progression with a reduction in
p21 and p27 in endothelial cells (Li Volti et al., 2005).
The relationship between HO1 and VEGF was carefully
investigated. Several studies, including ours, demonstra-
ted that this potent proangiogenic growth factor can
activate HO1 in endothelial cells (Bussolati et al., 2004;
Dulak et al., 2002; Jozkowicz et al., 2003b) – Figure 1.
Moreover, inhibition of HO1 activity by tin protopor-
phyrin prevented hypoxia-induced VEGF synthesis in
smooth muscle cells indicating the close interaction bet-
ween both proteins (Dulak et al., 2002).
As mentioned above, VEGF initiates a complex pro-
cess of angiogenesis. At the same time this protein, also
known as vascular permeability factor, increases vas-
cular permeability and allows plasma components and
inflammatory cells to exit the bloodstream. Additionally,
inflammatory cells can release various angiogenic cyto-
kines including VEGF (Sunderkotter et al., 1994). When
taking into account the anti-inflammatory properties of
HO1, one might think about a dual effect of this enzyme
in the vascular system. It seems that inflammation-indu-
ced angiogenesis, believed to play an important role in
e.g. in tumor growth, might be attenuated by increasing
HO1 activity in macrophages (Bussolati et al., 2004).
Hypoxic stimulation of gene expression is mediated
by the transcription factor HIF1α which binds to HRE in
the promoter region of several target genes involved in
the modulation of angiogenesis, ATP synthesis, oxygen
supply, and cell survival. Over the past two decades
more than 100 genes have been described as being regu-
lated by HIF1α (Pouyssegur et al., 2006). In fact, HRE
sequence is also present in the HO1 promoter and HO1
expression has been shown to be induced by hypoxia in
rodent vascular cells via HIF1 (Lee et al., 1997). Inte-
restingly, however, in many human cells, particularly
endothelial, the expression of HO1 is not induced or
even downregulated under hypoxic conditions (Kitamuro
et al., 2003). This is most probably associated with the
increased levels of BACH1, a hypoxia-inducible repres-
sor of HO1 (Fig. 2A). Nevertheless, the stimulatory ef-
fect of hypoxia (1% oxygen) on Vegf production by rat
vascular smooth muscle cells can be reverted by inhibi-
tors of Ho1 activity (Dulak et al., 2002). In human
HaCaT keratinocytes, hypoxic induction of HIF1 upregu-
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lates VEGF in an HO1-dependent manner, as the effect
is blunted by inhibitors of HO1 activity or HO1 siRNA
(Jazwa et al., 2006).
The proangiogenic effects of HO1 appear to be me-
diated in a large part by the actions of its reaction
byproduct, CO. CO, similar to nitric oxide, is able to acti-
vate soluble guanylate cyclase (Coceani, 1993). Once
activated, this enzyme converts GTP to cGMP and in-
creased intracellular cGMP leads to vasodilatation, inhi-
bition of smooth muscle cell proliferation, anti-thrombo-
genic effects, and anti-inflammatory responses in vas-
cular system (Forstermann and Munzel, 2006). Our
studies have demonstrated that CO can promote angio-
genesis via several mechanisms, including stimulation of
VEGF expression (Fig. 1). The treatment of vascular
smooth muscle cells with 1% CO gas (Dulak et al., 2002)
or endothelial cells with CO-releasing molecule 2 (Jozko-
wicz et al., 2003b) induces VEGF production. Moreover,
very recently CO has been shown to stimulate angio-
genesis in a paracrine mode of action because CO-media-
ted increase in HIF1α protein level in astrocytes induced
secretion of VEGF and led to the subsequent activation
of adjacent and surrounding endothelial cells to promote
angiogenesis (Choi et al., 2010). Interestingly, the au-
thors observed that CO increases HIF1α level by two dis-
tinct mechanisms: upregulation of protein synthesis by
activating the translational regulatory proteins p70 S6
kinase and eIF-4E through PI3K/AKT and MEK/ERK
pathways and inhibition of HIF1α degradation by promo-
ting the interaction of HIF1α with HSP90α (Choi et al.,
2010). The synergistic effect of HO1 and HIF1α activi-
ties has recently been demonstrated in vivo. A combined
delivery of their genes reduced apoptosis, increased
VEGF secretion and improved angiogenesis in ischemic
mouse hindlimbs to a greater extent than HO1 or HIF1α
single-gene therapy (Bhang et al., 2010).
In addition to VEGF, SDF1 has also been shown to
play an important role in the postnatal angiogenesis.
SDF1 is a chemokine that binds to a single high affinity
receptor, CXCR4. The main role of SDF1 is to promote
the migration of bone marrow-derived CXCR4+-endo-
thelial progenitor cells as well as hematopoietic cells to
local tissues, where they participate in neovasculariza-
tion (Ceradini and Gurtner, 2005). SDF1 increases HO1
expression, which in turn mediates SDF1-induced angio-
genic response of endothelial cells (Deshane et al.,
2007) – Figure 1. HO1 deficiency in endothelial cells
causes defective angiogenesis upon SDF1 stimulation.
Recently, HO1 has been shown to promote endothelial
progenitor cell mobilization and neovascularization after
hindlimb ischemia in mice (Tongers et al., 2008). In line
with these findings, local (Lin et al., 2008) and systemic
(Lin et al., 2009) HO1 gene transfer via adeno-associated
virus promoted neovascularization in the infarcted
hearts through the concurrent induction of VEGF and
SDF1 and the recruitment of bone marrow-derived
c-kit+-stem cells. Concomitant administration of both
VEGF and SDF1 neutralizing antibodies has significantly
attenuated HO1-mediated neovascularization and protec-
tion during myocardial infarction, highlighting the coope-
rative roles of both factors in HO1-mediated angio-
genesis and protection (Lin et al., 2008).
The cardioprotective effects of Hif1α subunit have
been shown to be dependent on HO1 activity (Czibik et
al., 2009). Very recently it has been suggested that HO1
and CO may actually have differential roles in cardiac
regeneration after myocardial infarction (Lakkisto et al.,
2010). CO, delivered in a form of methylene chloride
prior to coronary artery ligation in rats, promoted vas-
culogenesis and myocardial regeneration by activating
c-kit+stem/progenitor cells and promoting the differen-
tiation of stem cells to form new arteries and cardiomyo-
cytes through induction of Hif1α, Sdf1α and vascular
endothelial growth factor B synthesis. Instead, induction
of endogenous Ho1 with cobalt protoporhyrin IX appea-
red to promote angiogenesis by a CO-independent me-
chanism as Ho1 induced Sdf1α expression only (Lakkisto
et al., 2010). Although the authors do not comment on
that, it is possible that in their experimental setup, other
Ho1 activity products were involved in cardiac regenera-
tion and vascularization. It is also important to empha-
size that such HO1 inducers like protoporphyrins may
exert different unspecific effects (Jozkowicz and Dulak,
2003a) and CoPPIX has even been shown to downregu-
late the HIF1α expression in adult T-cell leukaemia cells
(Hamamura et al., 2007).
Role of iron and ferritin 
in HO1-mediated neovascularization
Heme released from a series of hemoproteins, inclu-
ding hemoglobin and cytochrome P450, is the natural
substrate for HO1 that increases its mRNA and activity
by several-fold (Yoshida et al., 1988). Once metabolized
by HO1 it gives rise to CO, biliverdin, and iron ions. Iron
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is an essential metal for all living organisms participating
in cellular processes, such as DNA synthesis, enzyme
functions, and oxygen transport. However, the biological
use of iron is limited by its low solubility and its propen-
sity to participate in the formation of potentially lethal
oxidizing agents. In the presence of superoxide and
hydrogen peroxide (H2O2), ferrous iron (Fe
2+) can cata-
lyze formation of the hydroxyl radical which is a powerful
oxidizing agent promoting lipid peroxidation, mutagene-
sis, DNA strand breaks, activation of oncogenes, and
tumor suppressor gene inhibition. Therefore, the rele-
ase of high amounts of reactive iron under the condi-
tions of strongly enhanced HO activity and a high supply
of heme may be potentially harmful to the cells (Suttner
and Dennery, 1999). On the other hand, HO1-dependent
release of free iron during heme catabolism results in
the upregulation of a secondary antioxidant protein, fer-
ritin (Eisenstein et al., 1991).
Ferritin is an intracellular protein that stores iron in
a nontoxic, yet bioavailable form (Torti and Torti, 2002).
This protein also exists in serum but has distinctive sub-
unit composition and low iron content. Ferritin is a bin-
ding partner of high molecular weight kininogen (HK),
a plasma protein involved in the intrinsic coagulation cas-
cade. Proteolytic cleavage of HK by kallikrein produces
two molecules that actually have opposing roles in angio-
genesis: proangiogenic bradykinin and 2-chain high mole-
cular weight kininogen (HKa) which is antiangiogenic.
It has been demonstrated that through the binding to
the antiangiogenic domain of HKa, ferritin antagonizes
HKa’s effects, leading to increased blood vessel growth
in a mouse tumor model (Coffman et al., 2009). Accor-
dingly, we have recently shown that upregulation of fer-
ritin in endothelial cells correlates with HO1 inducibility
and is significantly augmented in HUVEC cells carrying
cytoprotective short alleles of HO1 promoter (Taha et
al., 2010).
Iron can indirectly influence angiogenesis by acting
as a cofactor for enzymes involved in regulation of VEGF
synthesis or by enhancing oxidative stress (Ponka,
1999). Interestingly, we have previously observed that
deferoxamine, a nonpermeable iron chelator that extru-
des iron from cells, significantly enhanced Vegf synthe-
sis, whereas iron diminished its release by rat vascular
smooth muscle cells, both effects being mediated by
modulation of Hif1 activity (Dulak et al., 2002). Thus, it
can be hypothesized that an increased iron content
might, under certain conditions, attenuate VEGF-depen-
dent angiogenesis. It seems that these effects may vary
between cells and may result from their different capa-
bilities to achieve cellular iron homeostasis by upregula-
tion of HO1 or ferritin, or modulation of iron efflux.
It has been demonstrated that the extrusion of iron from
the cells requires active HO1 and it can be hypothesized
that the effect of HO1 on VEGF synthesis can be related
to the iron-pump activity of HO1 (Baranano et al., 2000;
Ferris et al., 1999).
Exogenous administration of HO1 
by gene therapy
Several lines of evidence indicate an important role
of HO1 in the cardiovascular system. The induction of
HO1 by gene therapy inhibits atherogenic plaque forma-
tion (Juan et al., 2001), attenuates vascular remodeling
following balloon injury (Tulis et al., 2001) and reduces
the infarct size in rats subjected to myocardial infarction
(Melo et al., 2002). These beneficial effects seem to be
related to the anti-proliferative, anti-thrombotic and anti-
inflammatory action of the end products of heme degra-
dation. Additionally, the therapeutic effects of HO1 in
several preclinical models of cardiovascular disease have
been linked to increased angiogenesis.
In a rat model of hindlimb ischemia, adenoviral deli-
very of rat Ho1 enhanced angiogenesis in the ischemic
muscles through the production of endogenous Vegf, an
effect being abrogated by inhibition of Ho1 activity (Su-
zuki et al., 2003). Importantly, it has been shown that
excessive accumulation of reactive iron at high HO1
levels may lead to increased oxidative stress, cytotoxi-
city, and abnormal cellular proliferation (Suttner and
Dennery, 1999). Therefore, when thinking about HO1
gene transfer it is worth emphasizing the importance of
a tight regulation of this gene expression. This objective
can be achieved by different means.
The concept of hypoxia-regulated HO1 gene transfer
was intensively investigated in different experimental
studies (Pachori et al., 2004; Pachori et al., 2006; Tang
et al., 2005; Tang et al., 2004) and seems to be a sui-
table strategy for the treatment of ischemic diseases by
reducing cellular damage during ischemia-reperfusion
injury, and preserving heart functions. This system is
based on HIF1α/HRE-mediated upregulation of the intro-
duced gene (Fig. 3). The main advantage of the use of
hypoxia-regulated vectors containing HRE sequence res-
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Fig. 3. The model of hypoxia-regulated HO1 expression. cDNA coding for HO1 is located downstream of minCMV promoter
and HRE sequence which constitutes the binding site for HIF1α/β heterodimer that activates transcription only in the absence
of oxygen, which happens e.g. under ischemic conditions associated with myocardial infarction. Increased HO1 activity generates
CO, which is a potent anti-inflammatory, anti-thrombotic and anti-apoptotic compound at low, physiological concentrations. Its
effect is, to a large extent, dependent on the activation of p38 mitogen-activated protein kinase. Heme-derived iron triggers
pathways involving the activation of ferritin, that further leads to its sequestration. Biliverdin (BV) and bilirubin (BR) produced
from HO1 activity also contribute to the cellular anti-oxidant balance. Altogether, an increased HO1 activity can exert protective
effects in ischemic tissues.
ponsible for sensing hypoxia is the induction of the
transgene expression in hypoxic tissues without thera-
peutic protein production in tissues unintentionally
transfected or transduced with a plasmid or viral vector.
Moreover, unlike the constitutive promoters which lead
to a constant production of proteins, the hypoxia-regula-
ted promoters enable overexpression of a therapeutic
agent that helps to overcome the ischemic assault in
statu nascendi and creates the possibility of a tight
regulation of HO1 expression (Fig. 3).
Another system providing control over the dosage
and temporal expression of a given gene product is
based on antibiotic-regulated vectors. The tetracycline
(Tet) On/Off gene control system has the prokaryotic
origin and is based on Tet resistance operon of E. coli.
Briefly, in the Tet-Off system the addition of an antibiotic
results in inactivation of transcription, while using Tet-
On system, the presence of an antibiotic activates the
expression of the gene of interest. Importantly, the Tet-
On system is about 100 times more sensitive to the Tet
analogue, doxycycyline, and therefore doxycycyline is
frequently used in this kind of studies. Tet-On/Off sy-
stem was used in different experimental settings inclu-
ding those based on HO1 overexpression (Suttner and
Dennery, 1999).
Role of HO1 in stem and progenitor cell function 
and efficiency of cell therapy
Cell therapy, similar to gene therapy, has been clai-
med to be effective in promoting neovascularization in
various preclinical models. Bone marrow-derived stem/
progenitor cells differentiate into circulating endothelial
progenitor cells (EPCs), and upon injury home in on to
the sites of ischemia and initiate neovascularization,
tissue/vessel remodeling, and cardiac regeneration most
probably by paracrine effects only (Losordo and Dim-
meler, 2004). Age-related and disease-linked impairment
of EPC may contribute to incorrect vascularization and
may be related to a loss of antioxidative defense. EPCs
express antioxidative enzymes, like catalase, glutathione
peroxidase-1, and manganese superoxide dismutase,
which make them resistant to oxidative stress (Dern-
bach et al., 2004). Therefore, it has been proposed that
genetic modifications of EPCs might restore and/or
improve their therapeutic function. In fact, experimental
overexpression of manganese superoxide dismutase (He
et al., 2004) enhanced EPC protection, whereas knock-
out of glutathione peroxidase-1 gene diminished the via-
bility and impaired vasculogenic potency of EPC (Gala-
sso et al., 2006). Our study demonstrated that the same
may apply to HO1 because the function of EPC in vitro
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and in vivo is impaired in mice that lack this gene
(Deshane et al., 2007).
It has been shown that the introduction of rabbit
EPCs into the denuded arteries enhanced the process of
reendothelialization (Kong et al., 2004). Additionally,
retroviral overexpression of endothelial nitric oxide syn-
thase in those EPCs significantly improved endothelial
regeneration. Transduction with human HO1, however,
did not affect the capacity of EPCs which, in the authors’
opinion, was probably related to the insufficient HO1
levels to generate CO in amounts required to enhance
endothelial cell proliferation (Kong et al., 2004). Further
examination of engineered stem cells, EPCs and other
tissue progenitors overexpressing HO1 would be of great
interest. According to our latest data, HO1 may be a
major regulator of microRNA transcriptome because it
strongly regulates the expression of many individual
microRNAs affecting satellite progenitor cells differentia-
tion to skeletal muscle (Ciesla et al., 2010).
Conclusions
In this review, we discuss the functional significance
of the HO1 system in the vascular bed and the potential
therapeutic applications of HO1 gene transfer in cardio-
vascular disease. Available data in animal models indi-
cate that patients suffering from cardiovascular patho-
logies might benefit from cardiovascular gene therapies
based on antioxidative, anti-apoptotic, anti-inflammatory
and proangiogenic properties of HO1 activity products,
namely CO and biliverdin/bilirubin. Moreover, it has
been proposed that moderate, tightly controlled HO1
expression by gene therapy should provide protection
against various toxic insults including reactive iron re-
leased in heme degradation. It is important to emphasize
that the treatment of human monogenic disorders with
gene therapy is now a reality and advances in scientific
and medical technologies may eventually create a possi-
bility for us to provide custom genetic therapy of cardio-
vascular disease.
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